The use of drug metabolism for prediction of intestinal permeability

Molecular Pharmaceutics

Volumn 6, Issue 1, 2009, Pages 74-81

  Chen, Mei Ling ^a   Yu, Lawrence ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

BCS; BDDCS; Biopharmaceutics classification system; Biopharmaceutics drug disposition classification system; Drug permeability

Indexed keywords

CAFFEINE; CARBAMAZEPINE; CILOMILAST; CYCLOSPORIN; DESIPRAMINE; DILTIAZEM; ENALAPRIL; FLUINDOSTATIN; GALANTAMINE; GLUCOSE; ISOTRETINOIN; KETOPROFEN; KETOROLAC; LABETALOL; LEUCINE; LEVODOPA; MEMANTINE; METRONIDAZOLE; NAPROXEN; NEVIRAPINE; PHENAZONE; PHENOBARBITAL; PHENYLALANINE; PHENYTOIN; PIROXICAM; PRIMAQUINE; PROPRANOLOL; ROSIGLITAZONE; SALICYLIC ACID; UNINDEXED DRUG; DRUG;

ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DISPOSITION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; PRIORITY JOURNAL; INTESTINE ABSORPTION; METABOLISM;

INTESTINAL ABSORPTION; PHARMACEUTICAL PREPARATIONS;

EID: 62649128592     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp8001864     Document Type: Article

References (67)

1. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
2. FDA Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Food and Drug Administration: Rockville, MD, 2000. Retrieved from www.fda.gov/cder/guidance/index.htm.
3. Lennernas, H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J. Pharm. Pharmacol. 1997, 49 (7)), 627-638.
4. Wu, C.-Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System. Pharm. Res. 2005, 22, 11-23.
5. Benet, L. Z.; Amidon, G. L.; Barends, D. M.; Lennernas, H.; Polli, J. E.; Shah, V. P.; Stavchansky, S. A.; Yu, L. X. The use of BDDCS in classifying the permeability ofmarketed drugs. Pharm. Res. 2008, 52, 483-488.
6. Takagi, T.; Ramachandran, C.; Bermejo, M.; Yamashita, S.; Yu, L. X.; Amidon, G. L. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain and Japan. Mol. Pharmaceutics 2006, 3, 631-643.
7. Lennernas, H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007, 37, 1015-1051.
8. Martina, S. D.; Ismail, M. S.; Vesta, K. S. Cilomilast: Orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann. Pharmacother. 2006, 40, 1822-1828.
9. Ochs, H. R.; Otten, H.; Greenblatt, D. J.; Dengler, H. J. Diazepam absorption: effects of age, sex, and Billroth gastrectomy. Dig. Dis. Sci. 1982, 27, 225-230.
10. Vaishali, P.; Stavchansky, S. Link between drug absorption, solubility and permeability measurements in Caco-2 cells. J. Pharm. Sci. 1998, 87, 1604-1607.
11. Physicians' Desk Reference (PDR), 2008. P.O. Box 2244, Willison, VT, U.S.A.
12. Jung, D.; Mroszczak, E.; Bynum, L. Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. Eur. J. Clin. Pharmacol. 1988, 35, 423-425.
13. Yang, Y.; Faustino, P. J.; Volpe, D. A.; Ellison, C. D.; Lyon, R. C.; Yu, L. X. Biopharmaceutics classification of selected β-blockers: Solubility and permeability class membership. Mol. Pharmaceutics 2007, 4, 608-614.
14. Urtasun, R. C.; Rabin, H. R.; Partington, J. Human pharmacoki- netics and toxicity on high-dose metronidazole administered orally and intravenously. Surgery 1983, 93 (1 Part 2), 145-148.
15. Smith, P. F.; DiCenzo, R.; Morse, G. D. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 2001, 40, 893-905.
16. Nelson, E.; Powell, J. R.; Conrad, K.; Likes, K.; Byers, J.; Baker, S.; Perrier, D. Phenobarbital pharmacokinetics and bioavailability in adults. J. Clin. Pharmacol. 1982, 22 (2-3), 141-148.
17. Mihaly, G. W.; Ward, S. A.; Edwards, G.; Nicholl, D. D.; Breckenridge, A. M. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br. J. Clin. Pharmacol. 1985, 19, 745-750.
18. Zaccara, G.; Messori, A.; Moroni, F. Clinical pharmacokinetics of valproic acid. Clin. Pharmacokinet. 1988, 15, 367-389.
19. Sumirtapura, Y. C.; Pamudji, J. S.; Ingriyani, I.; Sulistiyo, W.; Suhalim, H. Urinary excretion profiles of four oral cephalosporins in Indonesian healthy subjects. Acta Pharm. Indones. 2004, 29, 50-58.
20. Shyu, W. C.; Shah, V. R.; Campbell, D. A.; Wilber, R. B.; Pittman, K. A.; Barhaiya, R. H. Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans. J. Clin. Pharmacol. 1992, 32, 798-803.
21. Schwinghammer, T. L.; Norden, C. W.; Gill, E. Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects. J. Clin. Pharmacol. 1990, 30, 893-899.
22. Debruyne, D.; Pyckelynck, J. P. Clinical pharmcokinetics of fluconazole. Clin. Pharmacokinet. 1993, 24, 10-27.
23. Ramael, S.; Smedt, F. D.; Toublanc, N.; Otoul, C.; Boulanger, P.; Riethuisen, J.-M.; Stockis, A. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion with placebo in healthy subjects. Clin. Ther. 2006, 28, 734-744.
24. Fish, D. N.; Chow, A. T. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 1997, 32, 101-119.
25. Volpe, D. A. Permeability classification of representative fluoroquinolones by a cell culture method. AAPS J. 2004, 6 (2), 1-6.
26. Ward, M. E.; Musa, M. N.; Bailey, L. Clinical pharmacokinetics of lithium. J. Clin. Pharmacol. 1994, 34, 280-285.
27. Brogden, R. N.; McTavish, D. Loracarbef. A review of its microbial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993, 45, 716-736.
28. Flor, S. Pharmacokinetics of ofloxacin: An overview. Am. J. Med. 1989, 87 (6C), 24S-30S.
29. Kivisto, K. T.; Kroemer, H. K. Use of probe drugs as predictors of drug metabolism in humans. J. Clin. Pharmacol. 1997, 37 (Suppl), 40S-8.
30. Tassaneeyakul, W.; Birkett, D. J.; McManus, M. E.; Tassaneey- akul, W.; Veronese, M. E.; Andersson, T.; Tukey, R. H.; Miners, J. O. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol. 1994, 47, 1767-1776.
31. Giembycz, M. A. Cilomilast: A second generation phosphodi- esterase-4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Invest. Drugs. 2001, 10, 1361-1379.
32. Leonard, R. G.; Talbert, R. L. Calcium-channel blocking agents. Clin. Pharm. 1982, 1, 17-33.
33. Echizen, H.; Eichelbaum, M. Clinical pharmacokinetics of vera- pamil, nifedipine and diltiazem. Clin. Pharmacokinet. 1986, 11, 425-449.
34. Tessari, p.; Pehling, G.; Nissen, S. L.; Gerich, J. E.; Service, F. J.; Rizza, R. A.; Haymond, M. W. Regulation of whole-body leucine metabolism with insulin during mixed-meal absorption in normal and diabetic humans. Diabetes 1988, 37, 512-519.
35. Periclou, A.; Ventura, D.; Rao, N.; Abramowitz, W. Pharmaco- kinetic study of memantine in healthy and renally impaired subjects. Clin. Pharmacol. Ther. 2006, 79, 134-143.
36. Lau, A. H.; Lam, N. P.; Piscitelli, S. C.; Wilkes, L.; Danziger, L. H. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin. Pharmacokinet. 1992, 23, 328-364.
37. Evans, W. E., Schentag, J. J., Jusko, W. J., Eds. Applied Pharmacokinetics, 3rd ed.; Applied Therapeutics, Inc.: Vancouver, WA, 1992.
38. McGourty, J. C.; Silas, J. H.; Fleming, J. J.; Mcburney, A.; Ward, J. W. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. Clin. Pharmacol. Ther. 1985, 38, 409-413.
39. Brammer, K. W.; Farrow, P. R.; Faulkner, J. K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 1990, 12, S318-326.
40. 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur. J. Clin. Pharmacol. 2003, 59, 621-630.
41. Antonaccio, M. J.; Gomoll, A. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. Am. J. Cardiol. 1990, 65, 12A- 21A; discussion 35A-36A.
42. Carr, R. A.; Foster, R. T.; Lewanczuk, R. Z.; Hamilton, P. G. Pharmacokinetics of sotalol enantiomers in humans. J. Clin. Pharmacol. 1992, 32, 1105-1109.
43. Funck-Brentano, C. Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol. Eur Heart J. 1993, 4 (Suppl. H), 30-35.
44. Kasim, N. A.; Whitehouse, M.; Ramachandran, C.; Bermejo, M.; Lennernas, H.; Husssain, A. S.; Junginger, H. E.; Stavchansky, S. A.; Midha, K. K.; Shah, V. P.; Amidon, G. L. Molecular properties of WHO essential drugs and provisional biopharma- ceutical classification. Mol. Pharmaceitocs 2004, 1, 85-96.
45. Nozawa, T.; Toyobuku, H.; Kobayashi, D.; Kuruma, K.; Tsuji, A.; Tamai, I. Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer. J. Pharm. Sci. 2003, 92, 2208-2216.
46. Balimane, P. V.; Chong, S.; Patel, K.; Quan, Y.; Timoszyk, J.; Han, Y.-H.; Wang, B.; Vig, B.; Faria, T. N. Peptide transporter substrate identification during permeability screening in drug discovery: Comparison of transfected MDCK-hPepT1 Cells to Caco-2 cells. Arch. Pharm. Res. 2007, 30, 507-518.
47. Maeda, T.; Takahashi, K.; Ohtsu, N.; Oguma, T.; Ohnishi, T.; Atsumi, R.; Tamai, I. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol. Pharmaceutics 2006, 4, 85-94.
48. Dantzig, A. H.; Duckworth, D. C.; Tabas, L. B. Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells. Biochim. Biophys. Biomembr. 1994, 1191, 7-13.
49. Terashi, K.; Oka, M.; Soda, H.; Fukuda, M.; Kawabata, S.; Nakatomi, K.; Shiozawa, K.; Nakamura, T.; Tsukamoto, K.; Noguchi, Y.; Suenaga, M.; Tei, C. Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob. Agents Chemother. 2000, 1697-1700.
50. Axel, A.; Potthast, H.; Moessinger, J.; Sickmuller, B.; Oeser, H. Biopharmaceutical characterization of sotalol-containing oral immediate release drug products. Eur. J. Pharm. Biopharm. 2004, 58, 145-150.
51. Feng, B.; Obach, R. S.; Burstein, A. H.; Clark, D. J.; de Morris, S. M.; Faessel, H. M. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: A in vitro-in vivo study. Clin. Pharmacol. Ther. 2008, 83, 567-576.
52. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
53. Guyton, A. C.; Hall, J. E. Textbook of Medical Physiology, 9th ed.; W.B. Saunders Company: Philadelphia, PA, 1994.
54. Van de Waterbeemd, H. The fundamental variables of the biopharmaceutics classification (BCS): A commentary. Eur. J. Pharmacol. Sci. 1998, 7, 1-3.
55. Smith, D. A.; van de Waterbeemd, H. Pharmacokinetics and metabolism in early drug discovery. Curr. Opin. Chem. Biol. 1999, 3, 373-378.
56. Thummel, K. E. Gut instincts: CYP3A4 and intestinal drug metabolism. J. Clin. Invest. 2007, 117, 3173-3176.
57. Thummel, K. E.; Kunze, K. L.; Shen, D. D. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Delivery Rev. 1997, 27, 99-127.
58. Polinsky, R. J. Clinical pharmacology of rivastigmine: a new- generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin. Ther. 1998, 20, 634-647.
59. Baker, M.; Parton, T. Kinetic determination of hepatic clearance: Plasma protein binding and hepatic uptake. Xenobiotica 2007, 37, 1110-1134.
60. Blume, H. H.; Schug, B. S. The biopharmaceutics classification system (BCS): Class III drugs - better candidates for BA/BE waiver. Eur. J. Pharm. Sci. 1999, 9, 117-121.
61. Yu, L. X.; Amidon, G. L.; Poli, J. E.; Zhao, H.; Mehta, M. U.; Conner, D. P.; Shah, V. P.; Lesko, L. J.; Chen, M.-L.; Lee, V. H. L.; Hussain, A. S. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm. Res. 2002, 7, 921-925.
62. Linderberg, M.; Kopp, S.; Dressman, J. B. Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 2004, 58, 265-278.
63. Poli, J. E.; Yu, L. X.; Cook, J.; Amidon, G. L.; Borchardt, R. T.; Burnside, B. A.; Burton, P. S.; Chen, M.-L.; Conner, D. P.; Faustino, J.; Hawi, A. A.; Hussain, A. S.; Joshi, H. N.; Kwei, G.; Lee, V. H. L.; Lesko, L. J.; Lipper, R. A.; Loper, A. E.; Nerukar, S. G.; Polli, J. W.; Sanvordeker, D. R.; Taneja, R.; Upporr, R. S.; Vattikonda, C. S.; Wilding, I.; Zhang, G. Summary workshop report: Biopharmaceutics classification system - Implementation challenges and extension opportunities. J. Pharm. Sci. 2004, 93, 1375-1381.
64. Yazdanian, M.; Briggs, K.; Jankovski, C.; Hawi, A. The 'high solubility' definition of the current FDA guidance on biopharmaceutics classification system may be too strict for acidic drugs. Pharm. Res. 2004, 21, 293-299.
65. Rinaki, E.; Dokoumetzidis, A.; Valsami, G.; Macheras, P. Identification of biowaivers among Class II drugs: Theoretical justification and practical examples. Pharm. Res. 2004, 21, 1567-1572.
66. Lennernas, H.; Abrahamsson, B. The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension. J. Pharm. Pharmacol. 2005, 57, 273-285.
67. Fagerholm, U. Evaluation and suggested improvements of the biopharmaceutics classification system (BCS). J. Pharm. Pharmacol. 2007, 59, 751-757.